Patents by Inventor Keith Sadoon BAHJAT

Keith Sadoon BAHJAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies Binding to VISTA at Acidic pH
    Publication number: 20240092907
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: February 1, 2023
    Publication date: March 21, 2024
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
  • Antibodies binding to VISTA at acidic pH
    Patent number: 11603406
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 14, 2023
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
  • Antibodies Binding to Vista at Acidic pH
    Publication number: 20220073617
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: July 10, 2019
    Publication date: March 10, 2022
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
  • CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
    Patent number: 10983128
    Abstract: Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: April 20, 2021
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, Providence Health & Services
    Inventors: Keith Sadoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, Alan J. Korman
  • Antibodies Binding to Vista at Acidic pH
    Publication number: 20210017283
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: March 19, 2019
    Publication date: January 21, 2021
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
  • Antibodies Binding to VISTA at Acidic pH
    Publication number: 20200055936
    Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 20, 2020
    Applicants: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Andy X. Deng, Lin Hui Su, Ginger Rakestraw
  • CXCL11 AND SMICA AS PREDICTIVE BIOMARKERS FOR EFFICACY OF ANTI-CTLA4 IMMUNOTHERAPY
    Publication number: 20180246113
    Abstract: Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 30, 2018
    Applicants: BRISTOL-MYERS SQUIBB COMPANY, Providence Health & Services
    Inventors: Keith Sadoon BAHJAT, Helena Maria HOEN, Yoshinobu KOGUCHI, Alan J. KORMAN